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Abstract 
Background: The effectiveness of the combined oral contraceptive pill as a family planning 
method is dependent on its quality. The quality of medicines on the healthcare market is 
established through postmarket quality studies. 
Methods: The quality of the combined oral contraceptive pill was established through the 
collection of samples from 17 (62%) private retail pharmacies in the Nyeri town of Kenya. Their 
quality was then determined through the assay of content of levonorgestrel and ethinylestradiol and 
the levonorgestrel dissolution test at the National Quality Control Laboratory.  
Findings: 13 of the 17 pharmacies were licensed with the Pharmacy and Poisons Board while 4 
were unlicensed. Femiplan® was available in all the 17 pharmacies while Microgynon® was 
available in only 4 pharmacies. 17 samples of Femiplan® and 4 samples of Microgynon® were 
collected. None of the samples was counterfeit or falsely labeled. All the samples passed the assay 
of content of levonorgestrel and ethinylestradiol and the levonorgestrel dissolution test.   
Conclusion: Notwithstanding the fact this study provides a snapshot in time, it is reasonable to 
conclude that the combined oral contraceptive pill (0.15mg levonorgestrel and 0.03mg 
ethinylestradiol) in the Nyeri town of Kenya private retail pharmacies is of the right quality with 
respect to the quality tests of assay of content of levonorgestrel and ethinylestradiol and the 
levonorgestrel dissolution test. 
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1. Introduction 
Pharmaceutical services in Kenya are provided through the private and public sector (Ministry of 
Medical Services – Kenya 2010, p. 17). As of June 2015 there were 38 pharmaceutical 
manufacturers, approximately 250 wholesale pharmacies, 5,000 retail pharmacies and 12,000 
medicines registered in Kenya (Ministry of Medical Services – Kenya and World Health 
Organization 2010, p. 17). Public sector pharmaceutical services are provided through the 
Ministries of Health located at the National Government and the 47 County Governments 
(Ministry of Medical Services 2008). The Kenya Medical Supplies Agency, the Pharmacy and 
Poisons Board and the National Quality Control Laboratory are government agencies established 
for public sector medical supplies, medicines regulation and medicines quality testing 
respectively (Kenya Medical Supplies Agency 2015; National Quality Control Laboratory 2015).  
It is the responsibility of governments to promote and protect public health by ensuring that the 
medicines on the healthcare market are not of poor quality. A medicine is deemed to be of poor 
quality if it fails to meet the pharmacopoeial specifications it claims to comply with (Shakoor, 
Taylor and Behrens 1997; Kaur et al 2008; Hadi et al 2010). A poor quality medicine can have 
the wrong ingredients, inadequate amounts of the right ingredients, excess amounts of the right 
ingredients or the right ingredients in the right quantities but with a poor dissolution profile 
(Almuzaini, Choonara and Sammons 2013).  
The use of poor quality medicines leads to therapeutic failure and for antimicrobials this leads to 
spurious reporting of resistance (World Health Organization 2003; Newton et al 2006; 
Keoluangkhot et al 2008; World Health Organization 2012). Money spent on poor quality 
medicines is wasted (World Health Organization 2003; Alfadl et al 2006). Poor quality 
antimicrobials lead to development of antimicrobial resistance (World Health Organization 2003; 
Alfadl et al 2006; Newton et al 2006). Public confidence in healthcare systems is eroded by the 
finding of poor quality medicines in the healthcare market (World Health Organization 2003; 
Newton et al 2006; World Health Organization 2012). It is an exercise in futility to translate 
evidence from clinical trials into treatment protocols if the medicines actually used are of poor 
quality (Newton et al 2006; Newton et al 2009).  
The quality of medicines on the healthcare market is established through postmarket quality 
studies. Due to financial constraints, it is impossible for medicines regulatory authorities to 
collect samples of all medicines on the healthcare market at a given time and test their quality 
and therefore they adopt a risk and impact on public health approach in determining which 
medicines to sample. 
75% of all women in Kenya using contraceptives opt for hormonal contraceptives with 32% of 
them going for combined oral contraceptives (Republic of Kenya, Division of Reproductive 
Health 2009, p. 69). The combined oral contraceptive pill (0.15mg levonorgestrel and 0.03mg 
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ethinylestradiol) is listed in the 2013 World Health Organization Essential Medicines List and 
the 2010 Kenya Essential Medicines List (Republic of Kenya, Ministry of Medical Services and 
Ministry of Public Health and Sanitation 2010; World Health Organization 2013).  
The purpose of this project was to establish the quality of the combined oral contraceptive pill 
(0.15mg levonorgestrel and 0.03mg ethinylestradiol) in the private retail pharmacies of Nyeri 
Town, Kenya. This was with respect to the quality tests of assay of content of active 
pharmaceutical ingredients and dissolution. 
2.  Literature review 
    2.1. Medicines. Not your ordinary consumer product 
Medicines are not your ordinary consumer product owing to the asymmetry of information about 
medicines which exists between prescribers and consumers (Brundtland 1999; Rago and Santoso 
2008, p.66). Consumers find themselves not in a position to make decisions about when to use 
medicines, which medicines to use, how to use medicines and to weigh the potential benefits of 
medicines against their risks (Brundtland 1999; Rago and Santoso 2008, p.66). Healthcare 
professionals also do experience difficulties in making informed decisions on all aspects of 
medicines unless specially trained (Nikiema 2014).  
Therefore, medicines needs to be regulated with an aim of protecting and promoting public 
health and this is achieved through the following mutually reinforcing activities: the assessment 
of quality, safety and efficacy of medicines during market authorisation and postmarket, the 
licensing of manufacture, import, export, distribution and promotion of medicines, the inspection 
and surveillance of manufacturers, importers, wholesalers and retailers of medicines and last but 
not least the provision of independent medicines information to healthcare workers and the 
general public (World Health Organization 2003; Rago and Santoso 2008, p.67).  
    2.2. Medicines regulation. Historical perspectives 
Human beings have been taking medicines since history began (Penn 1979). The regulation of 
medicines is also not of recent origin. The ancient Egyptians had a flourishing medical 
profession in which physicians administered their medicines in accordance with a written law 
called the sacred book (Penn 1979). The Hippocratic Oath which originated after the 5
th
 Century 
BC enjoined the physician then and now against the giving of ‘pharmacon oudeni’ meaning 
lethal drug (Penn 1979; National Institutes of Health, National Library of Medicine, History of 
Medicine Division 2012). The medieval Muslim countries, in the early part of the 9
th
 century, 
established the office of the hisba headed by the muhtasib as the official responsible for 
enforcing public health regulations (Levey 1963). The muhtasib had specific instructions to 
inspect the drugs of the syrup makers while cautioning them not to flout medicines related public 
health regulations (Levey 1963). 
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Unfortunate events have played a significant role in the evolution of medicines regulatory 
frameworks (Rago and Santoso 2008, p.65). The enactment of the Federal Food, Drug and 
Cosmetic Act in the United States of America was hastened following the 1937 sulfanilamide 
disaster in which more than 100 people died after consuming an elixir sulfanilamide laced with 
diethylene glycol as the solvent (Bowie and McKenzie 1972; Ballentine 1981; Rago and Santoso 
2008, p.65). The thalidomide tragedy also had a major role in catalysing developments within the 
medicines regulatory frameworks (Rago and Santoso 2008, p.65-66). Thalidomide, a sedative 
and hypnotic drug, widely used as a morning sickness  treatment between 1958 and 1960, 
resulted in an estimated 10,000 babies being born with phocomelia worldwide (Rago and 
Santoso 2008, p.66; Tantibanchachai 2014). In 1963 the Australian Government formed the 
Australian Drug Evaluation Committee to evaluate the safety of medicines before they are 
offered for sale to its citizens in response to the thalidomide tragedy (Therapeutic Goods 
Administration 2014). The Drug Amendments of 1962 were enacted requiring that the United 
States Food and Drug Administration approve all new drug applications following demonstration 
of safety and efficacy (Rago and Santoso 2008, p.66; Tantibanchachai 2014). In the United 
Kingdom the Committee on the Safety of Medicines was established in 1963 following the 
thalidomide tragedy (Rago and Santoso 2008, p.66). 
Regrettably, unfortunate events are still catalysing developments in the medicine regulatory 
frameworks. In November 2013, President Barrack Obama signed into law the Compounding 
Quality Act to regulate the compounding of human drugs following the death of 64 people from 
meningitis contracted after receiving a fungi-contaminated methylprednisolone acetate injection 
produced by a Massachusetts-based compounding pharmacy (Gaffney 2013; The Lancet 2013 
Dennis 2014; Outterson 2014; United States Food and Drug Administration 2014).  
    2.3. Modern medicines regulatory frameworks 
Modern medicine regulatory frameworks are laid down by legislation to be enforced by 
government agencies known as medicines regulatory authorities.  Medicines regulatory 
authorities regulate the trade in medicines (human, veterinary and herbal) and a host of other 
products such as nutraceuticals, medical devices, in vitro diagnostics, food, cosmetics and 
tobacco products as provided for by legislation (Food and Drugs Authority Ghana 2014; 
Medicines and Healthcare Products Regulatory Agency 2014; Medicines Control Council 2014; 
Pharmacy and Poisons Board 2014; Therapeutic Goods Administration 2014; United States Food 
and Drug Administration 2014). The Pharmacy and Poisons Board of Kenya also regulates the 
practice of pharmacy. This is in contrast to other countries such as South Africa where we have 
the Medicines Control Council for medicines regulation and the South African Pharmacy 
Council for pharmacy practice regulation (Medicines Control Council 2014; South African 
Pharmacy Council 2014).  
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The most important function of medicines regulatory authorities is to ensure that the medicines 
on the healthcare market are not compromised with respect to quality, safety and efficacy. The 
quality of a medicine is of special significance since its compromise subsequently compromises 
the safety and/or efficacy of the medicine. Keoluangkhot and colleagues describe the case of an 
adult in Laos with uncomplicated malaria who failed to improve clinically following treatment 
with an artemether injection whose artemether content was 74% of the manufacturer’s label 
claim, a clear case of quality failures compromising the efficacy of medicines (Keoluangkhot et 
al 2008). The poor quality isosorbide mononitrate contaminated with a heavy dose of the 
antimalarial pyrimethamine supplied to patients in Pakistan in the year 2012 had a compromised 
safety evidenced by the death of 120 patients who used it (Arie 2012; The Lancet 2013). 
    2.4. What is a poor quality medicine? 
Before we delve further into matters ‘quality of medicines’ it is important that we gain an 
understanding of what is meant by the quality of a medicine. A medicine is deemed to be of poor 
quality when it fails to meet the pharmacopoeial specifications it claims to comply with 
(Shakoor, Taylor and Behrens 1997; Kaur et al 2008; Hadi et al 2010). A poor quality medicine 
can have the wrong ingredients, inadequate amounts of the right ingredients, excessive amounts 
of the right ingredients or the right ingredients in the right quantities but with a poor dissolution 
profile (Almuzaini, Choonara and Sammons 2013).  
Poor quality medicines can be genuine medicines produced by authorized manufacturers in 
which case they are referred to as substandard or out of specification medicines (Bate, Mooney 
and Milligan 2012; European Directorate for the Quality of Medicines and Healthcare of the 
Council of Europe2013; World Health Organization 2012). They can also be medicines that are 
illegally manufactured and fraudulently mislabeled with respect to identity or source in which 
case then they are referred to as counterfeit medicines (Bate, Mooney and Milligan 2012; World 
Health Organization 2012). 
    2.5. Poor quality medicines. Historical perspectives 
Human beings have been taking medicines since history began and poor quality medicines are 
perhaps as old as the medicines themselves (Penn 1979; World Health Organization 1999; 
Newton et al 2006; Rago and Santoso 2008, p.64). Dead flies adulterating the ointment of the 
apothecary, a person who prepares and sells medicines, appears as a comment in the Bible 
(Ecclesiastes 10:1, King James Version; Oxford Dictionaries 2014). The 17
th
 century witnessed 
the deliberate adulteration of the cinchona bark, the first effective treatment for malaria, with 
other astringent barks precipitated by the huge demand of the cinchona bark in the then malaria 
endemic Europe (Newton et al 2006; Cambridge University Library 2014).  
Our concern for the quality of medicines is also not of recent origin with the concepts for 
assuring the quality of medicines having evolved gradually over time (World Health 
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Organization 1999; Newton et al 2006; Rago and Santoso 2008, p.64). The first century AD, 
witnessed the Greek physician Pedanius Dioscorides advising on the dangers of adulterated 
medicines (World Health Organization 1999). The Materia Medica of Dioscorides highlighted 
some organoleptic tests for the detection of adulterated medicines (Penn 1979). The fine clay 
‘terra sigillata’ used from early Greek times for the treatment of wounds was made into round 
cakes and stamped with designs alluding to its  authenticity and quality (Penn 1979). In the 
medieval Muslim countries we had the muhtasib, official in charge of enforcing public health 
regulations, vested with powers to inspect the shops of the syrup makers (Levey 1963). The 
development of obligatory pharmacopoeial standards dates back to the 16
th
 century and the 1498 
New Compound Dispensatory issued by the Florentine guild of physicians and pharmacists for 
the apothecaries of Florence is regarded as the first official pharmacopoeia of a specific political 
unit in Europe (Penn 1979). 
    2.6. Need for the concern for quality of medicines 
The agenda of assuring the quality of medicines on the healthcare market should zealously be 
pursued by governments due to the following reasons. Firstly, the use of poor quality medicines 
can result in therapeutic failure with a subsequent increase in morbidity and mortality (World 
Health Organization 2003; Newton et al 2006; Keoluangkhot et al 2008; World Health 
Organization 2012). Secondly, the use of poor quality antimicrobials leads to development of 
resistance and this is especially undesirable among the sub-Saharan Africa high public health 
priority diseases specifically malaria, tuberculosis and the Acquired Immune Deficiency 
Syndrome (World Health Organization 2003; Alfadl et al 2006; Newton et al 2006). Thirdly, the 
detection of poor quality medicines on the healthcare market leads to erosion of public 
confidence in healthcare systems which can compromise the uptake of high public health priority 
healthcare services such as immunization (World Health Organization 2003; Newton et al 2006; 
World Health Organization 2012). Fourthly, it is a waste of resources to spend money on poor 
quality medicines whether individually or by governments (World Health Organization 2003; 
Alfadl et al 2006). Fifthly, the use of poor quality medicines leads to spurious reporting of 
resistance which can lead to unwarranted alterations of treatment protocols (Newton et al 2006). 
Lastly, it is an exercise in futility to translate evidence on drug treatment outcomes into treatment 
policy when the medicines actually used have inferior efficacy due to poor quality compared to 
the medicines originally tested during clinical trials or bioequivalence studies (Newton et al 
2006; Newton et al 2009).    
    2.7. Poor quality medicines. Now and recently 
Since the 17
th
 century adulteration of the cinchona bark, the world is still grappling with the 
problem of poor quality medicines notwithstanding the modern medicine regulatory frameworks. 
An Institute of Medicine of the National Academies report estimated that in the year 2011 
substandard or falsified medicines were sold in at least 124 countries worldwide (Institute of 
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Medicine of the National Academies 2013). Poor quality medicines are a problem for both the 
high and low income countries affecting both the expensive brands and cheap generics (World 
Health Organization 2012). Poor quality medicines have being witnessed in the medicines for the 
treatment of life-threatening conditions such as tuberculosis, medicines for the treatment of 
neglected tropical diseases such as visceral leishmaniasis and even in cheap generic versions of 
painkillers and antihistamines (Senior 2008; Dorlo et al 2012; World Health Organization 2012; 
Division of Malaria Control, Pharmacy and Poisons Board and National Quality Control 
Laboratory 2013). The problem of poor quality medicines appears to burden the low income 
countries more compared to the high income countries (Institute of Medicine of the National 
Academies 2013; The Lancet Editorial 2013). 
The world is still witnessing deaths occasioned by the use of medicines laced with diethylene 
glycol as the solvent and to mention a few: 7 deaths in South Africa in 1969, 14 deaths in India 
in 1986, 5 deaths in Spain in 1987, 85 deaths in Haiti in 1995, 33 deaths in India in 1998, 12 
deaths in China in 2008 and 57 deaths in Nigeria in 2008 (Bowie and McKenzie 1972; Singh et 
al 2001; Sosa et al 2014). 81 people died in the United States of America during the 2007-2008 
heparin crises after using a heparin batch contaminated with oversulfated chrondroitin sulfate 
(Briones 2008; Harris 2008). Avastin without active pharmaceutical ingredient was detected in 
the United States of America in the year 2012 (World Health Organization 2012). In June 2014, 
the United States Food and Drug Administration instituted a product recall of metoprolol 
succinate 100mg manufactured by Wockhardt Limited, India and metoprolol succinate 25mg 
manufactured by Dr. Reddy's Laboratories Limited, India after the two products failed 
dissolution tests, one of the basic tests of medicines quality (United States Food and Drug 
Administration 2014). 
In August 2008, health authorities in South Africa withdrew from the healthcare market two 
brands of antituberculosis medicines after World Health Organization accredited quality control 
tests indicated inadequate concentrations of rifampicin and isoniazid (Senior 2008). The lack of a 
substantial financial incentive in the market for medicines for Neglected Tropical Diseases has 
also not protected these medicines from poor quality batches (Dorlo et al 2012). In 2008, a 
generic miltefosine without the active pharmaceutical ingredient emerged in Bangladesh for use 
in the national leishmaniasis elimination programme (Senior 2008; Dorlo et al 2012). 
    2.8. Reasons for the availability of poor quality medicines  
 
There are various reasons for the availability of poor quality medicines on the healthcare market. 
The first one is the failure of medicine manufacturers to adhere to Good Manufacturing Practices 
(Bate, Mooney and Milligan 2012). The second reason is the pharmaceutical manufacturers’ use 
of poor quality pharmaceutical raw materials (Shakoor, Taylor and Behrens 1997). The third 
reason is the degradation of finished pharmaceutical products and pharmaceutical raw materials 
due to poor storage practices coupled with the high temperatures and humid conditions that 
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prevail in the tropical countries (Shakoor, Taylor and Behrens 1997; Taylor et al 2001). Lastly, 
we have the unscrupulous businessmen who guided by criminal greed engage in the production 
of poor quality medicines facilitated by lack of legislation criminalizing the production and 
marketing of poor quality medicines and if existent the failure of enforcement by government 
authorities and if enforced light penalties being imposed by the judiciary on the culprits (Newton 
et al 2006 and Onwujekwe et al 2009).  
    2.9. Measures for ridding the healthcare market of poor quality medicines 
There are various measures which medicine regulatory authorities can adopt to rid the healthcare 
market of poor quality medicines. The first one is the implementation of a robust marketing 
authorisation process encompassing a thorough evaluation of the quality data as presented on the 
Common Technical Document. The second measure is the conduct of regular and thorough 
inspection of pharmaceutical manufacturers to ensure that the manufacture of active 
pharmaceutical ingredients and finished pharmaceutical products adheres to Good 
Manufacturing Practices. 
The third measure entails the routine inspection of medicines distribution outlets in order to 
ensure that the medicines offered for sale are registered and that medicines distributors adheres 
to Good Distribution Practices by having for instance a system for batch tracing in case of poor 
quality medicinal product recall. The fourth measure entails having a paper and online based 
platform through which healthcare providers and the general public can report incidents of poor 
quality medicines. An example is the Pharmacy and Poisons Board poor quality medicinal 
product reporting form, also called the pink form, through which healthcare workers and the 
general public alert the Pharmacy and Poisons Board of any incidents of poor quality medicines 
(Pharmacy and Poisons Board 2014). The last and very important measure entails the conduct of 
regular postmarket quality studies. 
    2.10. Postmarket quality studies 
Postmarket quality studies entail the collection of medicines samples within a given geographical 
area and subjecting them to quality tests mainly the assay of content of active pharmaceutical 
ingredient(s) and dissolution. Postmarket quality studies can be conducted on a routine basis, 
following a complaint of a poor quality medicine or through sentinel site monitoring which 
entails the monitoring of the quality of medicines at a given site over a certain period of time.  
The benchmark for the postmarket quality of a medicine lies in its compliance with the laid down 
pharmacopoeial specifications it claims to comply with (Taylor et al 2001). A pharmacopoeia is 
an official book of medicines quality standards and the term is derived from the Greek word 
pharmaco-poios meaning drug-maker (United States Pharmacopeial Convention 2000; Rago and 
Santoso 2008, p.64; Rago and Santoso 2008, p.72). A pharmacopoeia is legally binding and 
contains the recommended quality specifications for the analysis and determination of medicinal 
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substances, specific dosage forms, excipients and finished pharmaceutical products (Rago and 
Santoso 2008, p.72). Quality specifications are composed of appropriate tests for confirming the 
identity and purity of medicinal products, ascertaining the amount of active pharmaceutical 
ingredients and the performance characteristics of medicinal products (Rago and Santoso 2008, 
p.72). The assay of content of active pharmaceutical ingredient(s) and the dissolution test are 
two quality specifications which find application in postmarket quality studies (Shakoor, Taylor 
and Behrens 1997; Taylor et al 2001; Laroche et al 2005; Alfadl, Abdoon, Elamin and Elnabi 
2006; Kaur et al 2008; Onwujekwe et al 2009; Hadi et al 2010; Bate, Mooney and Milligan 
2012; Evans et al 2012; Boateng 2013).  
 
Postmarket quality studies are also conducted by researchers affiliated to academic institutions 
and organizations such as the World Health Organization. The Promoting the Quality of 
Medicines program funded by the United States Agency for International Development and 
implemented by the United States Pharmacopeial Convention assists medicines regulatory 
authorities in the conduct of postmarket quality studies through financing and provision of 
technical assistance (Ghana Food and Drug Authority and The Promoting the Quality of 
Medicines Program 2013; United States Pharmacopeial Convention 2014). 
The Medicines Information and Pharmacovigilance Directorate of the Pharmacy and Poisons 
Board is the unit responsible for the conduct of postmarket quality studies in Kenya. This unit 
has for instance being monitoring the quality of antimalarials since the year 2011 with the results 
indicating that a significant proportion of antimalarials in the Kenyan healthcare market are of 
poor quality (Division of Malaria Control, Pharmacy and Poisons Board, National Quality 
Control Laboratory and The Promoting the Quality of Medicines Program 2011; Division of 
Malaria Control, Pharmacy and Poisons Board, National Quality Control Laboratory and The 
Promoting the Quality of Medicines Program 2012; Division of Malaria Control, Pharmacy and 
Poisons Board, National Quality Control Laboratory and The Promoting the Quality of 
Medicines Program 2013). 
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Table 1: Antimalarials postmarket quality studies results. Kenya 
                                            YEAR 
PARAMETERS 
 2011  2012  2013 
Samples collected 536 499 545 
Percentage of samples registered with the Pharmacy and Poisons 
Board 
94 97 99 
Samples analysed using minilab in the field – Level 1 519 496 514 
Percentage of samples that passed Level 1 minilab testing 92 97 95 
Samples analysed using minilab at the National Quality Control 
Laboratory – Level 2 
80 65 71 
Percentage of samples that passed Level 2 minilab testing 76 100 90 
Samples analysed using compendial methods at the National Quality 
Control Laboratory – Level 3 
44 25 20 
Percentage of samples that passed Level 3 compendial testing 84 76 90 
 
The average results are 5% failure at Level 1 minilab testing, 11% failure at level 2 minilab 
testing and 16% failure at level 3 for compendial testing. 
The Ghana Food and Drug Authority over the months of August and September 2012 assessed 
the postmarket quality of uterotonics (oxytocin injection, ergometrine injection and ergometrine 
tablets) in the Ghanaian healthcare market and found that a significant proportion of them failed 
the assay of content of active pharmaceutical ingredient (Ghana Food and Drug Authority and 
The Promoting the Quality of Medicines Program 2013). 
Table 2: Uterotonics postmarket quality study results. Ghana 
                                  MEDICINE 
PARAMETERS 
Oxytocin 
injection 
Ergometrine 
injection 
Ergometrine 
tablets 
Samples collected 185 103 15 
Samples subjected to the assay of content of active 
pharmaceutical ingredient  
169 99 11 
Percentage of samples which failed the assay of content of 
active pharmaceutical ingredient 
56 74 100 
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The Medicines and Healthcare Products Regulatory Agency, United Kingdom’s medicines 
regulatory authority, regularly identifies high risk medicines in need of postmarket quality 
surveillance based on a criteria such as patient exposure, product stability and impact and 
likelihood of risk (Medicines and Healthcare Products Regulatory Agency 2014). The 
postmarket quality of these medicines is then surveyed on a one off basis or continually sampled 
from pharmacies for authentication using a variety of analytical quality testing techniques 
(Medicines and Healthcare Products Regulatory Agency 2014). 
In the European Union, postmarket quality surveillance of centrally authorized and mutually 
recognized medicines is done by the General European Official Medicines Control Laboratory 
Network on behalf of the European Directorate for the Quality of Medicines and Healthcare 
(European Directorate for the Quality of Medicines and Healthcare of the Council of Europe 
2013). 20-25 Official Medicine Control Laboratories from 15-20 Member States participate in 
the scheme every year and the scheme results indicate a high level of quality is present in the 
medicines that are in use within the European Union since out of specification parameters have 
so far being found in only 2% of the medicines subjected to the surveillance programme 
(European Directorate for the Quality of Medicines and Healthcare of the Council of Europe 
2013).  
Postmarket quality studies published in various journals point toward a significant proportion of 
medicines circulating in the healthcare market of the low income countries been of poor quality. 
1912 antimalarials and antibiotics samples were collected from 11 African cities (Accra, Addis 
Ababa, Cairo, Dar es Salaam, Kampala, Kigali, Lagos, Luanda, Lubumbashi, Lusaka and 
Nairobi), 3 Indian cities (Delhi, Chennai and Kolkata) and 5 middle income countries cities (Sao 
Paolo, Moscow, Bangkok, Istanbul and Beijing) in 2012 and subjected to quality tests (Bate, 
Mooney and Milligan 2012). 3.8% of them failed quality tests performed with the Global Pharma 
Health Fund e.V. Minilab and 5.2% failing product authentication by Raman spectrometer (Bate, 
Mooney and Milligan 2012). 58% of 77 samples of antimalarials sampled in Guyana over the 
period of June and August 2009 failed quality control tests (Evans et al 2012). 18% of 104 
antibiotic samples collected from pharmacies in Indonesia in the year 2010 failed quality control 
tests (Hade et al 2010). Out of 713 samples of isoniazid and rifampicin purchased at community 
pharmacies in 19 cities of 17countries, 65 (9.1%) had insufficient active pharmaceutical 
ingredient with the failure rate being 9.1% in Africa, 10.1% in India and 3.9% in other middle-
income countries (Bate et al 2013; Binagwaho et al 2013). 
Postmarket quality studies conducted in the low income countries have tended to focus more on 
antimicrobials most probably due to the high burden of infectious and communicable diseases. A 
search of medical literature on EMBASE, MEDLINE, Google Scholar, PubMed and 
International Pharmaceutical Abstracts for postmarket quality studies on combined oral 
contraceptives yielded no results. It is imperative that postmarket quality studies are conducted to 
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establish the quality of the combined oral contraceptives circulating in the Kenyan healthcare 
market. 
    2.11. Combined oral contraceptives 
Contraception, also referred to as birth control, entails the use of various medical devices, drugs, 
sexual practices or surgical procedures to prevent pregnancy (Nordqvist 2012; The State of 
Queensland 2014). Contraception is achieved either by prevention of fertilization of the female 
egg by the male sperm or by prevention of implantation of the fertilized egg in the uterus 
(Kimathi, Micheni and Muriithi 2002, p.87).  
There are various methods of contraception available in Kenya and these include: the natural 
family planning method also called periodic abstinence or fertility awareness method, the barrier 
methods such as the male condom, female condom, diaphragm and sponges, the surgical 
contraception method through tubal ligation for women and vasectomy for men, the intrauterine 
contraceptive devices which can be copper based or hormonal and lastly we have the hormonal 
contraceptives administered as combined  oral contraceptives, progestogen only contraceptives, 
intramuscular shots and implants or delivered through the transdermal patch, the vaginal ring and 
the hormonal intrauterine contraceptive device (Kimathi, Micheni and Muriithi 2002, p. 91-92; 
Crouch 2009, p. 489-490; Republic of Kenya, Division of Reproductive Health 2009 p. 21). 
Hormonal contraceptives can either be progestogen-only or combined hormonal contraceptives 
(Amin et al 2012, p. 514). The progestogen-only contraceptives are classified into oral 
progestogen only contraceptives, intra-uterine progestogen-only devices and the parenteral 
progestogen-only contraceptives which are administered through deep intramuscular injections 
or as subcutaneous implants (Crouch 2009, p. 493, Amin et al 2012, p. 521; McEvoy et al, 2013, 
p. 3118). The combined hormonal contraceptives combine an oestrogen and a progestogen and 
are administered through the combined oral contraceptive pill, the vaginal contraceptive ring or 
the transdermal contraceptive patch (Amin et al 2012, p. 515; McEvoy et al 2013, p. 3103).  
Majority of the combined oral contraceptive pills contain ethinylestradiol as the oestrogen 
component with the progestogen component being one of the following progestogens: 
levonorgestrel, norgestrel, ethynodiol, desogestrel, gestodene, drospirenone, norethisterone, 
norethindrone, norgestimate or dienogest (Amin et al 2012, p. 519-520; McEvoy et al 2013, p. 
3116-3117). The readily available brands of the combined oral contraceptive pills in Kenya are 
composed of 0.15mg levonorgestrel and 0.03mg ethinylestradiol. The combined oral 
contraceptive pills can also be monophasic or phasic (Amin et al 2012, p. 515; McEvoy et al 
2013, p. 3104). The monophasic ones contain a fixed amount of an oestrogen and a progestogen 
in each of the active tablets in a cycle while the phasic ones contain varying amounts of the two 
hormones in a cycle and in that case they can be biphasic, triphasic or estrophasic (Amin et al 
2012, p. 515; McEvoy 2013, p. 3104). 
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The combined oral contraceptive pills achieve their contraceptive effect through an interplay of 
several factors with the most important being the inhibition of ovulation and the thickening of 
the cervical mucus thus providing a physical barrier to spermatozoa (Crouch 2009, p. 491; Bayer 
Pharma AG 2011; McEvoy et al 2013, p. 3114). They also make the endometrium too thin for 
implantation (Crouch 2009, p. 491). The inhibition of ovulation is through suppression of the 
hypothalamic-pituitary system with the oestrogen component suppressing secretion of the 
follicle-stimulating hormone and the progestogen component inhibiting the preovulatory rise of 
the luteinizing hormone (McEvoy 2013, p. 3114).  
It is the responsibility of governments to ensure that the medicines and medical devices 
employed as methods of contraception are not quality compromised since this has an impact on 
their effectiveness as methods of contraception. Contraception is the platform through which we 
practice family planning (World Health Organization 2014). Family planning enables us to bring 
forth life when it is wanted, expected and welcome (Kimathi, Micheni and Muriithi 2002, p 87; 
Crouch 2009, p. 488). In addition, a woman’s ability to utilize contraception to space and limit 
her pregnancies has a direct impact on her health and the outcome of each pregnancy (World 
Health Organization 2014). Family planning plays a central role in the achievement of the 
Millenium Development Goals reiterated by the 2005 revision of the Millenium Development 
Goal number 5 through addition of Target 5.B on attainment of universal access to reproductive 
health under which we have two direct family planning indicators namely: the contraceptive 
prevalence rate and the unmet need for family planning (Republic of Kenya, Division of 
Reproductive Health 2009 p. 1; United Nations 2014). Family planning is an essential priority 
component in the Kenya Essential Package for Health and the Kenya National Reproductive 
Health Policy 2009-2015 (Crouch 2009, p. 488; Republic of Kenya, Division of Reproductive 
Health 2010, p. 2). 
A particular method of contraception for which governments should be concerned about its 
postmarket quality is the combined oral contraceptive pill containing 0.15mg levonorgestrel 
and 0.03mg ethinylestradiol. This is due to the following reasons. Firstly, a significant number 
of women in Kenya use the combined oral contraceptive pill as a family planning method. 
Nearly 75% of all women in Kenya using contraceptives opt for hormonal contraceptives with 
32% of them going for the combined oral contraceptive pill (Republic of Kenya, Division of 
Reproductive Health 2010, p.69). Secondly, the combined oral contraceptive pill (0.15mg 
levonorgestrel and 0.03mg ethinylestradiol) is listed as an essential medicine in the 2013 World 
Health Organization Essential Medicines List and the 2010 Kenya Essential Medicines List 
(Republic of Kenya, Ministry of Medical Services and Ministry of Public Health and Sanitation 
2010; World Health Organization 2013). Thirdly, every Kenyan has a right under the 
Constitution of Kenya to access the highest attainable standards of healthcare. This includes the 
right to access family planning methods which are of the right quality. Lastly, the combined oral 
contraceptive pill is also used in emergency contraception and has non-contraception uses such 
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as the treatment of acne, hirsutism and premenstrual mood syndrome (Crouch 2009, p.492; 
Republic of Kenya, Division of Reproductive Health 2010, p.71; Republic of Kenya, Division of 
Reproductive Health 2010, p.105; McEvoy et al 2013, p.3106).  
In Kenya various healthcare providers are engaged in the provision of the combined oral 
contraceptive pill as a family planning method with one of the main providers being the private 
retail pharmacies where it is sold without prescription (Republic of Kenya, Division of 
Reproductive Health 2010, p.21).  
3. Methodology 
    3.1. Background. 
Medicines regulatory authorities conduct postmarket quality studies either on a routine basis, 
following a poor quality medicinal product complaint or through sentinel site monitoring. 
Sentinel site monitoring entails the monitoring of the quality of a medicine in a given site over a 
certain period of time. Postmarket quality studies entail the collection of medicines samples from 
the healthcare market which are then subjected to pharmacopoeial based quality tests mainly the 
assay of content of active pharmaceutical ingredients and the dissolution test. 
Informed decisions on the minimum number of samples to be collected in postmarket quality 
studies so as to be representative for a given geographical area are hindered by a lack of reliable 
data on the prevalence of poor quality medicines and on the proportion of pharmacies selling 
poor quality medicines. This is especially so for combined oral contraceptives where a search of 
medical literature revealed not a single postmarket quality study on the combined oral 
contraceptive pill (0.15mg levonorgestrel and 0.03mg ethinylestradiol).  
The Pharmacy and Poisons Board employs two methods in the collection of samples during 
postmarket quality studies. The first one entails the collection of samples from a randomly 
selected list of pharmacies in a given geographical area. The second one is through the 
convenience sampling method which is potentially flawed by bias since the sample collectors 
target the more geographically accessible pharmacies. The covert (simulation-client) and overt 
methods of sample purchase are applied as the case may be. 
After consultation with the Pharmacy and Poisons Board, it was decided that samples be 
collected from the private retail pharmacies only as this was part of a study been conducted by 
the Pharmacy and Poisons Board targeting a wider range of reproductive health medicinal 
products available in the private and public pharmaceutical sectors of Kenya. This explains why 
samples were not collected from the public sector as had been stated in the research proposal.  
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The readily available brands of the combined oral contraceptive pill (0.15mg levonorgestrel and 
0.03mg ethinylestradiol) in the private pharmaceutical sector of Kenya are Femiplan® and 
Microgynon®. This project therefore focused on these 2 brands.  
    3.2. Geographical area of study 
The geographical area of focus in this project was the Nyeri town of Kenya. Nyeri town is the 
headquarters of Nyeri County. Nyeri is one of the 47 counties in Kenya. 
    3.3. Selection of private retail pharmacies for sample collection 
All the 27 private retail pharmacies in Nyeri town were mapped by noting down their names and 
locations. The Pharmacy and Poisons Board was consulted on their licensure status and it was 
established that 23 are licensed while 4 are unlicensed. The 4 unlicensed premises were selected 
for sample collection and from the remaining 23 pharmacies 13 were randomly selected for 
sample collection. A total of 17 private retail pharmacies were therefore selected for sample 
collection representing 62% of the total number of private retail pharmacies in Nyeri town.  
    3.4. Samples collection 
A sample was defined as that number of tablets bearing the same proprietary name, with similar 
content and strength of active pharmaceutical ingredients, bearing the same batch number and 
procured from a given pharmacy. Collection of samples was done on the 28
th
 and 29
th
 of August, 
2014 through the covert/simulation-client method. Two covert shoppers were engaged to pose as 
customers. The typical user of the combined oral contraceptive pill as a family planning method 
is a female aged 20-40 years and the 2 covert shoppers fitted this profile. 1 covert shopper was 
engaged in the purchase of Femiplan® pills and the other one for the purchase of Microgynon® 
pills. The covert shoppers were trained on what to say while making the purchases and were also 
under instruction to purchase 3 cycles of either Femiplan® or Microgynon® as the case may be. 
3 cycles provided 63 tablets of the combined oral contraceptive pill.  
 
Sample coding and filling of the sample collection form was done immediately the covert 
shopper left a given retail pharmacy and before the next purchase was done. The sample 
collection forms were dated and indicated the name and location of the pharmacy concerned and 
the following details regarding the sample: proprietary name, name and strengths of active 
pharmaceutical ingredients, quantity collected, batch number, date of manufacture, expiry date, 
name and address of the manufacturer as indicated on the pack and lastly the name and address 
of the marketing authorisation holder as indicated on the pack. The nomenclature used to code 
the samples was COC/xxx/yyy with COC being combined oral contraceptive abbreviated, xxx 
being the facility code incremental from 001 as the pharmacies are visited and samples collected 
and yyy being the sample number also incremental from 001 as the samples are collected and 
coded. 
 
 
 
 
 15 
 
    3.5. Samples submission to the Pharmacy and Poisons Board  
All the samples were checked to confirm that they had more than 6 months left to their expiry 
date. The samples were then digitally photographed using a Sony Digital Still Camera model 
number DSC-W350 and all the pertinent sample details tabulated in a Microsoft Office Excel 97-
2003 worksheet. All the samples package colour and writings were visually inspected for 
obvious signs of counterfeiting. The samples were retained in their point-of-purchase packaging, 
sealed in individual plastic bags, packed in a carton and stored in a lockable cabinet at room 
temperature prior to transport to the Pharmacy and Poisons Board.  
A form for submitting samples to the Pharmacy and Poisons Board was duly filled indicating the 
following sample details: sample code, facility name, brand name, stated manufactured by, batch 
number, expiry date and the quantity. The samples were delivered and received at the Pharmacy 
and Poisons Board on 21 September 2014. 
    3.6. Samples submission to the National Quality Control Laboratory 
A sample analysis request form was filled for each of the samples requesting for identification, 
assay and dissolution tests for levonorgestrel and ethinylestradiol. The samples were submitted 
to the National Quality Control Laboratory on 16 October 2014.  
    3.7. Assay of the content of levonorgestrel and ethinylestradiol 
The average of the 10 individual results obtained in the test for uniformity of content was used in 
the assay.  
The test for uniformity of content was conducted through the High Performance Liquid 
Chromatography method in accordance with the British Pharmacopoeia 2012 Volume V 
Appendix XII C. The internal standard method was applied using the following stock solutions: 
Solution A containing 0.0625% weight/volume of levonorgestrel British Pharmacopoeia 
Chemical Reference Substance, Solution B containing 0.025% weight/volume of ethinylestradiol 
British Pharmacopoeia Chemical Reference Substance, Solution C containing 0.020% 
weight/volume of 2-hydroxylbiphenyl (internal standard) and Solution D from dilution of 1 
milliliter of Solution C to 20 milliliter with the solvent mixture. 
Solutions for the chromatography were then prepared as follows: Solution 1 by mixing the 
volumes of solutions A and B as specified in the compendia with 5 milliliter of solution C and 
diluting to 100 milliliter with a mixture of 40 volumes of water and 60 volumes of acetonitrile 
and Solution 2 by adding 4 milliliter of solution D to one tablet and heating at 60 degrees 
centigrade in an ultrasonic bath for 25 minutes and then shaking for a repeat ultrasound 
treatment. This was then cooled and the clear supernatant fluid used. 
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The chromatographic procedure was then carried out using a stainless steel column (15 
centimetres by 4.6 millimetres) packed with octadecylsilyl silica gel (5 micrometre), a mixture of 
49 volumes of acetonitrile and 51 volumes of water as the mobile phase with a flow rate of 1.5 
millilitres per minute and a detection wavelength of 215 nanometres. 
The content of levonorgestrel and ethinylestradiol in each tablet was calculated using the 
declared content of levonorgestrel in the British Pharmacopoeia Levonorgestrel Chemical 
Reference Substance and the declared content of ethinylestradiol in the British Pharmacopoeia 
Ethinylestradiol Chemical Reference Substance. 
The specification for levonorgestrel and ethinylestradiol was 90.0 - 110.0 % of the label claim. 
    3.8. Levonorgestrel dissolution test 
Poor manufacturing practices, degradation due to poor storage and the use of incorrect excipients 
results in medicines with poor dissolution and a subsequent compromised bioavailability.  
The ethinylestradiol dissolution analysis was not done due to lack of a spectrofluorometric 
detector. Levonorgestrel dissolution analysis utilizes an Ultraviolet 247 nanometres detector 
which was available.  
The levonorgestrel dissolution test was carried out through the High Performance Liquid 
Chromatography method with compendia adopted from the United States Pharmacopoeia 37 
National Formulary 32 Volume 3 page 3542. The medium consisted of polysorbate 80 (5 
micrograms/gram) in water with acetonitrile and water (6:4) as the mobile phase. The United 
States Pharmacopoeia Levonorgestrel Reference Standard solution was prepared in medium 
having known concentrations that would be obtained by dissolving 1 tablet in 500 millilitres of 
the medium. The sample solution was prepared by withdrawing 15 millilitres portions of liquid 
from each vessel and passing through a polyvinylidene filter and discarding the first 10 millilitre 
of the filtrate. The chromatographic system consisted of a column of 4 millimeters by 15 
centimeters with a flow rate of 1 milliliter per minute and an injection size of 100 microliters. 
The percentage of levonorgestrel dissolved was calculated using the below formulae 
Result = ( rU / rS ) x ( CS / CU ) x 100  
 
rU = peak response of the corresponding analyte from the Sample solution 
rS = peak response from the corresponding analyte from the Standard solution 
CS = concentration of the appropriate United States Pharmacopoeia Reference Standard in the 
Standard solution (micrograms/milliliter) 
CU = nominal concentration of the corresponding analyte in the Sample solution 
(micrograms/milliliter) 
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The tolerance limit for levonorgestrel was that not less than 65% of the labeled amount of 
levonorgestrel should be dissolved.    
4. FINDINGS, ANALYSIS AND DISCUSSION 
    4.1. Pharmacies, samples availability and registration status 
 
There were 27 private retail pharmacies in Nyeri town at the time of sample collection. 23 were 
licensed with the Pharmacy and Poisons Board while 4 were unlicensed. 17 (62%) pharmacies 
were selected and visited for sample collection. Femiplan® was available in all the 17 
pharmacies while Microgynon® was available in 4 pharmacies. 17 samples of Femiplan® and 4 
samples of Microgynon® were collected giving a total of 21 samples. 20 of the samples had 63 
hormone-containing tablets each while 1 sample had 42 hormone-containing tablets. Femiplan® 
and Microgynon® are registered with the Pharmacy and Poisons Board. 
 
    4.2. Pertinent sample descriptors 
1 cycle of Microgynon® consisted of 21 hormone-containing beige coated tablets and 7 
hormone-free brown coated tablets while that of Femiplan® consisted of 21 hormone-containing 
yellow tablets and 7 hormone-free brown tablets. 
The hormone-free tablets contained 75mg of ferrous fumarate. 
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Table 3: Pertinent sample descriptors (N = 21) 
SAMPLE CODE BATCH NUMBER EXPIRY DATE SAMPLE SIZE (TABLETS) 
COC/001/001 FN306 Feb 2018 63 
COC/002/002 FN301 Dec 2017 63 
COC/003/003 FN204 Nov 2017 63 
COC/004/004 FN304 Jan 2018 63 
COC/005/005 FN301 Dec 2017 63 
COC/006/006 FN304 Jan 2018 42 
COC/007/007 FN303 Jan 2018 63 
COC/008/008 FN304 Jan 2018 63 
COC/009/009 FN304 Jan 2018 63 
COC/010/010 FN302 Dec 2017 63 
COC/011/011 FN304 Jan 2018 63 
COC/012/012 FN306 Feb 2018 63 
COC/013/013 FN304 Jan 2018 63 
COC/014/014 FN303 Jan 2018 63 
COC/015/015 FN304 Jan 2018 63 
COC/005/016 32375A Mar 2018 63 
COC/008/017 32375A Mar 2018 63 
COC/017/018 FN304 Jan 2018 63 
COC/002/019 381A Mar 2017 63 
COC/016/020 FN304 Jan 2018 63 
COC/012/021 32375A Mar 2018 63 
 
    4.3. Visual inspection of the samples  
A visual inspection of the samples did not reveal any counterfeit or falsely labeled batches. 
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    4.4. Assay and dissolution test results 
The label claim for Femiplan® and Microgynon® was 0.15mg levonorgestrel and 0.03mg 
ethinylestradiol. Femiplan® label claim specified the British Pharmacopoeia while that for 
Microgynon® was not specific on the pharmacopoeia.  
Levonorgestrel and ethinylestradiol assay was done in accordance with the British 
Pharmacopoeia while the levonorgestrel dissolution test was adopted from the United States 
Pharmacopoeia. Both pharmacopoeias are recognized in Kenya for testing the quality of 
medicines. 
All the samples passed the identification test, the assay of content of levonorgestrel and 
ethinylestradiol and the levonorgestrel dissolution test. NOTE - The ethinylestradiol dissolution 
test was not conducted due to the laboratory lacking a spectrofluorometric detector for the liquid 
chromatographic system.  
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Table 4: Results of assay of content of levonorgestrel and ethinylestradiol and the levonorgestrel 
dissolution test (N = 21) 
Sample code Assay 
Specification: 90.0 – 110.0% of the labeled amount 
Dissolution 
Specification: No tablet with less than 65% of 
the labeled amount is dissolved 
Levonorgestrel 
determination (%) 
Ethinylestradiol 
determination (%) 
Remarks Levonorgestrel 
determination 
(%) 
Remarks 
COC/001/001 97.2 97.2 COMPLIES 96.2 COMPLIES 
COC/002/002 96.9 105.7 COMPLIES 95.7 COMPLIES 
COC/003/003 95.2 94.0 COMPLIES 97.2 COMPLIES 
COC/004/004 98.3 99.6 COMPLIES 97.6 COMPLIES 
COC/005/005 97.1 97.3 COMPLIES 97.8 COMPLIES 
COC/006/006 103.9 104.1 COMPLIES 105.3 COMPLIES 
COC/007/007 97.2 98.5 COMPLIES 98.7 COMPLIES 
COC/008/008 97.9 98.5 COMPLIES 98.1 COMPLIES 
COC/009/009 96.8 96.9 COMPLIES 97.3 COMPLIES 
COC/010/010 97.1 99.8 COMPLIES 97.2 COMPLIES 
COC/011/011 97.4 98.7 COMPLIES 98.1 COMPLIES 
COC/012/012 97.9 100.2 COMPLIES 98.3 COMPLIES 
COC/013/013 97.6 98.8 COMPLIES 98.9 COMPLIES 
COC/014/014 102.2 101.2 COMPLIES 101.8 COMPLIES 
COC/015/015 96.7 96.9 COMPLIES 96.6 COMPLIES 
COC/005/016 103.1 101.4 COMPLIES 102.9 COMPLIES 
COC/008/017 104.5 101.1 COMPLIES 104.3 COMPLIES 
COC/017/018 102.8 103.6 COMPLIES 99.4 COMPLIES 
COC/002/019 102.0 101.8 COMPLIES 101.9 COMPLIES 
COC/016/020 105.8 103.5 COMPLIES 105.4 COMPLIES 
COC/012/021 103.8 100.2 COMPLIES 103.1 COMPLIES 
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NOTE: For 3 samples, the laboratory reported that they were insufficient samples to carry out an 
out of specification investigation for the test of uniformity of content for ethinylestradiol (sample 
COC/002/002, COC/006/006 and COC/010/010) and levonorgestrel (sample COC/006/006). 
These did not impact on the assay since as earlier stated the assay was determined from the 
average of the 10 individual results obtained in the test for uniformity of content.   
4.5 Discussion 
Due to financial constraints, it is virtually impossible for a medicines regulatory authority to 
conduct laboratory quality tests an all samples of medicinal products available in the healthcare 
market. Therefore, a likelihood of risk and impact on public health approach is adopted in 
determining which medicinal products to routinely sample and test for quality.  
The aim of this research project was to establish the quality of the combined oral contraceptive 
pill (0.15mg levonorgestrel and 0.03mg ethinylestradiol) in the private retail pharmacies of Nyeri 
town, Kenya. This was as part of a larger study by the Pharmacy and Poisons Board covering a 
wider range of reproductive healthcare products circulating in the private and public 
pharmaceutical sector of Kenya. The quality determination was to be pegged on the quality tests 
of assay and dissolution for levonorgestrel and ethinylestradiol.  
This research project reports positive results. None of the samples was found to be counterfeit 
and they all passed the levonorgestrel and ethinylestradiol assay and the levonorgestrel 
dissolution test. Regrettably, it was not possible to characterize the quality of the samples with 
respect to the ethinylestradiol dissolution test due to a technical hitch at the laboratory 
occasioned by the lack of a spectrofluorometric detector in the liquid chromatographic system 
which indicates some capacity issues at the National Quality Control Laboratory. 
These positive results indicate that the manufacturers of the concerned sample brands adhere to 
Good Manufacturing Practices and that the products are handled and stored well throughout the 
distribution chain. Poor manufacturing and distribution practices have been identified as causes 
of substandard medicines in the healthcare market (World Health Organization 2015). There are 
no studies in literature on the postmarket quality of combined oral contraceptives in Kenya for 
comparison purposes. Therefore, this and the wider study to be reported by the Pharmacy and 
Poisons Board would be useful for comparing with future studies. 
This project was not without limitations and it is imperative that we appreciate them as we draw 
our conclusions. Firstly, the quality of the combined oral contraceptive pills was not 
characterized with respect to the ethinylestradiol dissolution test. Secondly, a cross-sectional 
study such as this research project provides a snapshot in time about the quality of medicines on 
the healthcare market. Thirdly, the Marketing Authorisation Holders of the sample brands were 
not contacted to authenticate the samples. Authentication relied wholly on the visual inspection 
of the samples by the researcher. Fourthly, lack of previous studies on the postmarket quality of 
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combined oral contraceptive pills in the Kenyan private retail pharmaceutical sector was a 
hindrance to the determination of appropriate sample sizes. Lastly, the number of tablets 
available per sample was not sufficient enough to have samples reserved for retesting. This was 
due to the limited number of tablets a mystery shopper could purchase without arousing 
suspicion. This is one of the limitations of using the covert as opposed to the overt method in the 
purchase of samples.  
5. Conclusions and recommendations 
Considering that none of the samples was counterfeit and that they all passed the levonorgestrel 
and ethinylestradiol assay and the levonorgestrel dissolution test, it is reasonable to conclude 
that the combined oral contraceptive pill (0.15mg levonorgestrel and 0.03mg ethinylestradiol) 
circulating in the Nyeri town of Kenya private retail pharmacies is of the right quality. This 
conclusion is drawn only with regard to the quality tests of levonorgestrel and ethinylestradiol 
assay and the levonorgestrel dissolution analysis. The ethinylestradiol dissolution analysis was 
not conducted.   
There are various recommendations which can be made from this research project. Firstly, 
postmarket quality studies on reproductive healthcare products including but not limited to 
combined oral contraceptive pills should routinely be conducted by the Pharmacy and Poisons 
Board covering both the private and public pharmaceutical sectors. In consideration of the 
financial burden of analysis, a criterion of likelihood of risk and impact on public health would 
be useful in determining which medicines to sample. Secondly, the Ministry of Health 
Government of Kenya needs to consider how it can subsidize the cost of analysis at the National 
Quality Control Laboratory. It cost approximately 7,500 United States Dollars to analyse the 21 
samples in this research project. This huge cost of analysis is the main impediment to the 
conduct of postmarket quality studies on a routine basis by the Pharmacy and Poisons Board.  
Thirdly, for three of the samples (sample codes COC/002/002, COC/006/006 and COC/010/010) 
which the laboratory reported that they were insufficient samples to conduct a uniformity of 
dosage unit out of specification investigation, it is recommended that those samples with those 
specific batch numbers be overtly purchased from the market and submitted for analysis at the 
National Quality Control Laboratory. Fourthly, the National Quality Control Laboratory needs to 
be equipped with a spectrofluorometric detector in the High Performance Liquid 
Chromatography system. Lastly, all the unlicensed private retail pharmacies in Nyeri town 
should be closed down and criminal sanctions be imposed on the owners. 
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7. Appendices 
    7.1. Research proposal 
Title  
An assessment of the quality of Combined Oral Contraceptive pills containing Ethinylestradiol 
0.03mg and Levonorgestrel 0.15mg in the Nyeri Town of Kenya pharmaceuticals market. 
Introduction 
It is the ultimate responsibility of drug regulatory authorities to ensure that pharmaceuticals in 
the healthcare market are of the right quality. In this regard, various strategies are adopted by 
drug regulatory authorities in this quest and they include among others implementing a robust 
initial marketing authorisation regime, conducting regular Good Manufacturing Practices audits 
of pharmaceutical manufacturers, conducting regular Good Distribution Practices audits of 
pharmaceutical distributors and lastly conducting regular postmarket surveillance of 
pharmaceuticals in the pharmaceuticals market in order to single out the poor quality 
pharmaceutical products with or without a market authorisation.  
A class of pharmaceutical products deserving of postmarket surveillance in spite of the limited 
resources that the drug regulatory authorities in the developing countries such as Kenya have is 
the Combined Oral Contraceptive pill containing Ethinylestradiol 0.03mg and Levonorgestrel 
0.15mg. This is due to the following factors. Firstly, in Kenya nearly 75% of all women using 
modern contraceptives choose hormonal methods with 32% opting for the Combined Oral 
Contraceptive pill (Republic of Kenya 2010). Secondly, the Combined Oral Contraceptive 
containing Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg is listed as an essential drug in 
the Kenya Essential Medicines List which makes it readily available in both the public and 
private healthcare markets (Republic of Kenya 2010). Lastly, Combined Oral Contraceptives 
containing Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg have other health benefits apart 
from family planning and are prescribed for dysmenorrhoea, irregular cycles, emergency 
contraception and premenstrual mood syndrome (Republic of Kenya 2010). 
Pursuant to the foregoing, the researcher is seeking approval of his research proposal which will 
entail an assessment of the quality of sampled Combined Oral Contraceptives containing 
Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg in the Nyeri town of Kenya pharmaceutical 
market. The assessment of quality will be through assay and dissolution tests and the proposed 
site of analysis will be the National Quality Control Laboratory in Kenya. 
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Methodology 
Nyeri town in Kenya is home to 26 identified distribution points for the Combined Oral 
Contraceptives containing Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg and these include 
3 public hospitals, 1 private hospital, 2 wholesale dealers in pharmaceuticals, 3 private medical 
centres and 17 retail pharmaceutical outlets. 
In this regard, this research will entail collection of samples of Combined Oral Contraceptives 
containing Ethinylestradiol 0.03mg and Levonorgestrel 0.15mg at the following 13 sampling 
sites / distribution points: 3 public hospitals, 2 wholesale dealers in pharmaceuticals, 1 private 
hospital, 3 private medical centres and 4 retail pharmaceutical outlets. 
It is envisaged that a sample will consist of a minimum of 100 tablets and a sample will be 
regarded as distinct based on the batch/lot number. The researcher targets a total of 12 samples 
as a minimum. It is worth noting, and this has a bearing on the determination of the sample size, 
that there are 3 brands of Combined Oral Contraceptives containing Ethinylestradiol 0.03mg and 
Levonorgestrel 0.15mg which are registered with the Pharmacy and Poisons Board and thus 
authorized to be in the Kenyan market. 
The samples will be subjected to quality tests specifically assay and dissolution tests at the 
National Quality Control Laboratory. The National Quality Control Laboratory is mandated by 
the Pharmacy and Poisons Act (2002) of the Laws of Kenya as a testing facility for 
pharmaceuticals. 
Ethical considerations 
This research does not entail the collection of samples from research participants so there is no 
ethical approval issues envisaged. The researcher will foot the bill for the cost of analyzing the 
samples the National Quality Control Laboratory. The results of the research will be forwarded 
to the Pharmacy and Poisons Board of Kenya, the Division of Reproductive Health Ministry of 
Health, the Director of Health Nyeri County and lastly the owners of the pharmaceutical outlets 
where the Combined Oral Contraceptive pills containing Ethinylestradiol 0.03mg and 
Levonorgestrel 0.15mg will be sampled from. 
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    7.2. Sample collection form 
RESEARCH PROJECT TITLE. 
An assessment of the quality of the Combined Oral Contraceptive pill - Ethinylestradiol 0.03mg 
and Levonorgestrel 0.15mg in the Nyeri Town of Kenya pharmaceuticals market. 
 
SAMPLE COLLECTION FORM. 
1. Date ………………………….. 
2. Name and address of health facility  
……………………………………………………………………………………………… 
P.O. Box ………………………………………….. Postal code …………………………. 
Physical location …………………………………………………………………………... 
3. Facility code ………………………………… 
4. Sample code ………………………………… 
5. Sample brand name ………………………………………………………………………... 
6. Sample active pharmaceutical ingredients including strength  
………………………………………………………………………………………………
……………………………………………………………………………………………… 
7. Dosage form ……………………………………………………………………………….. 
8. Sample quantity collected …………………………………………………………………. 
9. Batch number ……………………………………………………………………………… 
10. Date of manufacture ………………………………………………………………………. 
11. Expiry date ………………………………………………………………………………… 
12. Name and address of the manufacturer (as indicated on the pack). 
……………………………………………………………………………………………… 
……………………………………………………………………………………………… 
13. Country of origin of the product (as indicated on the pack). 
……………………………………………………………………………………………… 
14. Name and address of the marketing authorisation holder. 
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
Sample collection done and witnessed by. 
 
S/N NAME DESIGNATION SIGNATURE 
1  
 
  
2  
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    7.3. Sample photos 
Sample code: COC/001/001 
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Sample code: COC/002/002 
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Sample code: COC/003/003 
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Sample code: COC/004/004 
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Sample code: COC/005/005 
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Sample code: COC/006/006 
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Sample code: COC/007/007 
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Sample code: COC/008/008 
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Sample code: COC/009/009 
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Sample code: COC/010/010 
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Sample code: COC/011/011 
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Sample code: COC/012/012 
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Sample code: COC/013/013 
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Sample code: COC/014/014 
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Sample code: COC/015/015 
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Sample code: COC/005/016 
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Sample code: COC/008/017 
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Sample code: COC/017/018 
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Sample code: COC/002/019 
 
 
 
 
 
 
 
 
 
 56 
 
Sample code: COC/016/020 
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Sample code: COC/012/021 
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7.4. Certificates of analysis 
                 Sample code: COC/001/001 
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                Sample code: COC/002/002 
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                 Sample Code: COC/003/003 
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      Sample Code: COC/004/004 
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      Sample Code: COC/005/005 
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    Sample code: COC/006/006 
 
 
 
 
 
 64 
 
                 Sample Code: COC/007/007 
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       Sample Code: COC/008/008 
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       Sample Code: COC/009/009 
 
 
 
 
 
 
 
 
 67 
 
    Sample code: COC/010/010 
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                 Sample Code: COC/011/011 
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      Sample Code: COC/012/012 
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      Sample Code: COC/013/013 
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      Sample Code: COC/014/014 
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      Sample Code: COC/015/015 
 
 
 
 
 
 
 
 
 73 
 
      Sample Code: COC/005/016 
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      Sample Code: COC/008/017 
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       Sample Code: COC/017/018 
 
 
 
 
 
 
 
 
 76 
 
      Sample Code: COC/002/019 
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      Sample Code: COC/016/020 
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      Sample Code: COC/012/021 
 
 
 
 
 
